Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 6/20 | 0.56 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.56 |
| ▸ | CALCR | P30988 | 3/20 | 0.56 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | GLP1R | P43220 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658382 | 0.93 | CALCR (0.67) | VIPR1CALCRCRHR1CRHR2KEAP1 | |
| SCHEMBL29528965 | 0.90 | VIPR2 (0.62) | VIPR2VIPR1CALCRCRHR1CRHR2 | |
| SCHEMBL7454951 | 0.89 | GLP1R (0.55) | VIPR2VIPR1CALCRCRHR1CRHR2 | |
| SCHEMBL7454936 | 0.89 | GLP1R (0.55) | VIPR2VIPR1CALCRCRHR1CRHR2 | |
| SCHEMBL29934195 | 0.89 | GLP1R (0.51) | VIPR2VIPR1CALCRKEAP1GLP1R | |
| SCHEMBL30576930 | 0.89 | KEAP1 (0.61) | VIPR2CALCRKEAP1GLP1R | |
| SCHEMBL31295725 | 0.88 | CALCR (0.55) | VIPR2VIPR1CALCRCRHR1CRHR2 | |
| SCHEMBL29742728 | 0.88 | VIPR2 (0.57) | VIPR2VIPR1CRHR1CRHR2KEAP1 | |
| SCHEMBL31182938 | 0.88 | GLP1R (0.62) | CALCRKEAP1GLP1R | |
| SCHEMBL29416079 | 0.88 | KEAP1 (0.58) | VIPR2VIPR1CALCRKEAP1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240350475-A1 | TRIGONELLINE MITIGATES CARDIOMYOPATHY CAUSED BY SARS-COV-2 SPIKE PROTEIN UNDER OBESITY | UNIVERSITY OF SOUTH CAROLINA (US) | 2024-10-24 | — | — | US | disclosed |